An interventional study of Individualized Intermittent Theta-Burst Stimulation and Sham Intermittent Theta-Burst Stimulation in Irritable Bowel Syndrome (IBS) and Depressive Symptoms, sponsored by The Affiliated Hospital of Hangzhou Normal University. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by The Affiliated Hospital of Hangzhou Normal University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies in Irritable Bowel Syndrome with a site in China — 27 open to participants now, 27 under way, 3 of them phase 3. Irritable Bowel Syndrome · China.
Among the 74 studies in Irritable Bowel Syndrome with a site in China, this one is the 45th largest by planned enrollment of the 56 interventional ones that give a count, is one of 10 that started in 2024, is one of 26 with no phase, reaches primary completion later than 20 of the 26 other live ones, and was the 74th registered.
1,117 studies on the registry are indexed under Irritable Bowel Syndrome; 209 are open to participants now.
Browse Irritable Bowel Syndrome studies →27 of the 74 studies in Irritable Bowel Syndrome with a site in China are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in China, United States, Belgium and 7 more countries
Ages 18–75
Eli Lilly and Company · Sites in China, United States, Belgium and 5 more countries
Ages 18–75
Beijing Tiantan Hospital · Sites in China
Ages 18–70
Tang-Du Hospital · Sites in China
Ages 18–60 · Healthy volunteers
Chen QiYi · Sites in China
Ages 3+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 127 Irritable Bowel Syndrome studies recruiting now, 33 (26%) set no upper age limit and 84 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 14 · Phase 3 10 · Phase 4 8
First in 2008; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 70 across 896 interventional studies indexed under Irritable Bowel Syndrome.
Median enrollment 160 across the 56 interventional studies, 160 across the 18 observational. Of the 24 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 74 have an industry lead sponsor. The 10 most frequent:
The Affiliated Hospital of Hangzhou Normal University is the lead sponsor of 11 studies on the registry; 11 are open to participants now.
The Affiliated Hospital of Hangzhou Normal University has 2 studies filed under Irritable Bowel Syndrome — fewer than ten, so there is no comparison to draw.
8 of the studies in Irritable Bowel Syndrome with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07646834Tang-Du HospitalAnxiety and Depression in IBS: A Brain-Gut Axis Study | 2026-12-21 |
| NCT06788444Beijing Tiantan HospitalEfficacy of Esketamine for Patients With Irritable Bowel Syndrome | 2026-12-31 |
| NCT05740319Shanghai Zhongshan HospitalEfficacy and Safety Evaluation of Fecal Microbiota Transplantation in Irritable Bowel Syndrome | 2026-12-31 |
| NCT07545772Eli Lilly and CompanyA Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) | 2027-07 |
| NCT07721012Lei Yunshang GroupHuanghou Zhixie Diwan in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) | 2027-08-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 74 studies in Irritable Bowel Syndrome with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized, double-blind, sham-controlled trial aims to evaluate the effects of individualized intermittent theta-burst stimulation (iTBS) on depressive and gastrointestinal symptoms in patients with irritable bowel syndrome (IBS) and depressive symptoms.
A total of 60 eligible participants will be randomly assigned in a 1:1 ratio to active or sham stimulation. Individualized stimulation targets within the left dorsolateral prefrontal cortex (DLPFC) will be identified using resting-state functional magnetic resonance imaging (fMRI).
Participants will receive 10 stimulation sessions over two weeks. Clinical assessments and multimodal brain MRI will be performed at baseline and at the end of Week 2. The primary outcome will be the change in depressive symptom severity measured by the 17-item Hamilton Depression Rating Scale (HAMD-17).
An optional ancillary study involving paired stool sample collection at baseline and Week 2 is planned to support future exploratory investigations of gut microbiota and its associations with clinical symptoms and brain network characteristics. This ancillary component will be implemented only after the relevant ethics approval and additional informed consent have been obtained.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive individualized intermittent theta-burst stimulation targeting the left dorsolateral prefrontal cortex. The stimulation target will be identified using resting-state fMRI-guided functional connectivity analysis. Stimulation will be delivered at 90% of the resting motor threshold, with 1,800 pulses per session. Each session will comprise three blocks of 600 pulses, separated by approximately 15-minute intervals. Participants will receive five sessions per week for two weeks, for a total of 10 sessions.
Device: Individualized Intermittent Theta-Burst Stimulation
Participants will undergo a sham stimulation procedure with a schedule comparable to the active intervention. The stimulation coil will be positioned at 90 degrees to minimize effective cortical stimulation. Participants will receive five sessions per week for two weeks, for a total of 10 sessions.
Device: Sham Intermittent Theta-Burst Stimulation
Resting-state fMRI-guided iTBS targeting the individualized left dorsolateral prefrontal cortex at 90% of resting motor threshold, delivering 1,800 pulses per session for 10 sessions over two weeks.
A sham stimulation procedure using a coil positioned at 90 degrees, with a treatment schedule comparable to active iTBS.
Change From Baseline in Depressive Symptom Severity Assessed by HAMD-17 at Week 2
Depressive symptom severity will be assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17). A higher score indicates greater depressive symptom severity. The change from baseline to the end of Week 2 will be compared between the active and sham stimulation groups.
Time frame: Baseline and end of Week 2
Change From Baseline in IBS Symptom Severity at Week 2
IBS symptom severity will be assessed using the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS). Changes from baseline to the end of Week 2 will be compared between groups.
Time frame: Baseline and end of Week 2
Change From Baseline in Abdominal Pain Intensity at Week 2
Abdominal pain intensity will be evaluated using a Visual Analog Scale (VAS).
Time frame: Baseline and end of Week 2
Change From Baseline in Pain Severity Assessed by the Short-Form McGill Pain Questionnaire at Week 2
Pain-related symptoms will be assessed using the Short-Form McGill Pain Questionnaire (SF-MPQ).
Time frame: Baseline and end of Week 2
Change From Baseline in Anxiety Symptom Severity at Week 2
Anxiety symptom severity will be assessed using the 14-item Hamilton Anxiety Rating Scale (HAMA-14).
Time frame: Baseline and end of Week 2
Change From Baseline in IBS-Related Quality of Life at Week 2
IBS-related quality of life will be assessed using the Irritable Bowel Syndrome Quality of Life questionnaire (IBS-QOL).
Time frame: Baseline and end of Week 2
MRI Outcomes
functional and structural brain network analyses
Time frame: Baseline and end of Week 2
Safety Outcomes
adverse-event incidence
Time frame: Baseline and end of Week 2
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.
Of 305 non-industry interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's planned 36 months is above that.
Counting every sponsor, half of 357 studies reached it within 19 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Affiliated Hospital of Hangzhou Normal University